// Research
"Bone is far more than a structural scaffold, and, in disease, it becomes a privileged site for cancer to grow"
— Paul Bourgine, Principal Investigator
PURPOSE
Bone is the body's most underestimated organ. It makes blood, instructs immunity, and in disease becomes the place where cancer is hardest to reach. Understanding how that happens at the cellular and molecular level, is our work.
// THEMES OF RESEARCH
Four lines of inquiry
Each addresses a distinct biological question while sharing common technologies, cell sources, and a commitment to human specific experimental models.
// collaborations
Translation
and partnerships
Our work extends beyond the lab through Dhalion Biotech AB, a spin off company advancing our cell-free bone graft technology and the personalized modeling of cancers.
Dhalion Biotech AB
Clinical translation of the OssiGel bone graft technology
Dhalion Biotech AB is the lab's spin-off company, co-founded by Paul Bourgine to bring the OssiGel bone matrix technology toward clinical application. It is the translational arm of the lab's regenerative graft research, addressing the reconstruction of large bone defects.
Academic & industry partners
Collaborations
The Bourgine Lab works within an international network of academic and industry partners. Collaborations span clinical centres, research universities, and biotechnology companies across Europe and beyond bringing complementary expertise in haematology, immunology, materials science, and clinical translation.nd more. To change and reuse text themes, go to Site Styles.
Academic collaborations include joint projects with groups at ETH Zürich, the University of Basel, and partner institutions within the Lund University research community. Industry collaboration is anchored by Dhalion Biotech AB, the lab's spin-off company focused on translating the OssiGel bone matrix technology into clinical application.